

# Martin C Burke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10619223/publications.pdf>

Version: 2024-02-01

50  
papers

3,519  
citations

186265

28  
h-index

214800

47  
g-index

50  
all docs

50  
docs citations

50  
times ranked

2070  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator. <i>Circulation</i> , 2013, 128, 944-953.	1.6	486
2	Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1605-1615.	2.8	458
3	Subcutaneous or Transvenous Defibrillator Therapy. <i>New England Journal of Medicine</i> , 2020, 383, 526-536.	27.0	278
4	Head-to-Head Comparison of Arrhythmia Discrimination Performance of Subcutaneous and Transvenous ICD Arrhythmia Detection Algorithms: The START Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 359-366.	1.7	192
5	Atrial Fibrillation After Radiofrequency Ablation of Type I Atrial Flutter. <i>Circulation</i> , 1998, 98, 315-322.	1.6	151
6	Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. <i>Heart Rhythm</i> , 2017, 14, 1456-1463.	0.7	137
7	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. <i>Circulation</i> , 2021, 143, 7-17.	1.6	132
8	Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2018, 15, 1515-1522.	0.7	123
9	Atypical Atrial Flutter Originating in the Right Atrial Free Wall. <i>Circulation</i> , 2000, 101, 270-279.	1.6	107
10	A New Algorithm to Reduce Inappropriate Therapy in the S-ICD System. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 417-423.	1.7	107
11	3D Echocardiographic Location of Implantable Device Leads and Mechanism of Associated Tricuspid Regurgitation. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 337-347.	5.3	97
12	The learning curve associated with the introduction of the subcutaneous implantable defibrillator. <i>Europace</i> , 2016, 18, 1010-1015.	1.7	95
13	A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score. <i>Heart Rhythm</i> , 2019, 16, 403-410.	0.7	94
14	Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. <i>Heart Rhythm</i> , 2016, 13, 1066-1074.	0.7	92
15	Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2014, 11, 1352-1358.	0.7	86
16	Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. <i>Heart Rhythm</i> , 2016, 13, 157-164.	0.7	67
17	Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8). <i>Heart Rhythm</i> , 2006, 3, 967-970.	0.7	64
18	Postmortem Interrogation and Retrieval of Implantable Pacemakers and Defibrillators: A Survey of Morticians and Patients. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 478-482.	1.7	58

#	ARTICLE	IF	CITATIONS
19	Implications and Outcome of Permanent Coronary Sinus Lead Extraction and Reimplantation. <i>Journal of Cardiovascular Electrophysiology</i> , 2005, 16, 830-837.	1.7	57
20	Acute and 3-Month Performance of Communicating Leadless Antitachycardia Pacemaker and Subcutaneous Implantable Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1487-1498.	3.2	57
21	Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. <i>Heart Rhythm</i> , 2019, 16, 1636-1644.	0.7	48
22	Impact of Implantable Transvenous Device Lead Location on Severity of Tricuspid Regurgitation. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 1164-1175.	2.8	44
23	Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized Comparative trial of Subcutaneous Implantable Cardioverter-Defibrillator Implantation with and without Defibrillation testing. <i>American Heart Journal</i> , 2019, 214, 167-174.	2.7	41
24	Ranolazine Safely Decreases Ventricular and Atrial Fibrillation in Timothy Syndrome (LQT8). <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, e62-4.	1.2	35
25	Anesthesia for subcutaneous implantable cardioverter-defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 807-816.	1.2	35
26	Impact of Body Mass Index on Safety and Efficacy of the Subcutaneous Implantable Cardioverter-Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 652-659.	3.2	34
27	Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e006665.	4.8	33
28	Defibrillation energy requirements using a left anterior chest cutaneous to subcutaneous shocking vector: Implications for a total subcutaneous implantable defibrillator. <i>Heart Rhythm</i> , 2005, 2, 1332-1338.	0.7	32
29	Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. <i>Heart Rhythm</i> , 2017, 14, 367-375.	0.7	30
30	Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial. <i>Circulation</i> , 2022, 145, 321-329.	1.6	28
31	Outcomes in Patients With Congenital Heart Disease Receiving the Subcutaneous Implantable-Cardioverter Defibrillator. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 615-622.	3.2	26
32	1-Year Prospective Evaluation of Clinical Outcomes and Shocks. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1537-1550.	3.2	24
33	The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 1-8.	1.2	22
34	Integration of cardiac imaging and electrophysiology during catheter ablation procedures for atrial fibrillation. <i>Journal of Electrocardiology</i> , 2006, 39, S188-S192.	0.9	19
35	Direct imaging of transvenous radiofrequency cardiac ablation using a steerable fiberoptic infrared endoscope. <i>Heart Rhythm</i> , 2005, 2, 1116-1121.	0.7	16
36	Device orientation of a leadless pacemaker and subcutaneous implantable cardioverter-defibrillator in canine and human subjects and the effect on intrabody communication. <i>Europace</i> , 2018, 20, 1866-1871.	1.7	16

#	ARTICLE	IF	CITATIONS
37	Frozen shoulder syndrome associated with subpectoral defibrillator implantation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1999, 3, 253-256.	1.3	15
38	Long-term performance of a novel communicating antitachycardia pacing-enabled leadless pacemaker and subcutaneous implantable cardioverter-defibrillator system: A comprehensive preclinical study. <i>Heart Rhythm</i> , 2022, , .	0.7	15
39	Medtronic Sprint Fidelis lead recall: Determining the initial 5-year management cost to Medicare. <i>Heart Rhythm</i> , 2011, 8, 1192-1197.	0.7	12
40	Postmortem Analysis and Retrieval of Implantable Pacemakers and Defibrillators. <i>New England Journal of Medicine</i> , 2006, 354, 1649-1650.	27.0	11
41	Percutaneous extraction of coronary sinus vein and branch leads. <i>Heart Rhythm</i> , 2008, 5, 491-495.	0.7	10
42	Feasibility of an Entirely Extracardiac, Minimally Invasive, Temporary Pacing System. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007182.	4.8	9
43	Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. <i>Heart Rhythm</i> , 2020, 17, 1566-1574.	0.7	9
44	Analysis of electrocardiograms for subcutaneous monitors. <i>Journal of Electrocardiology</i> , 2003, 36, 227-232.	0.9	7
45	Outcomes of two versus three incision techniques: Results from the subcutaneous ICD post-approval study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 792-801.	1.7	7
46	Late Manifestation of Coronary Sinus and Left Atrial Perforation of a Left Ventricular Pacemaker Lead at Extraction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 502-506.	1.2	2
47	The infinite value in subcutaneous defibrillation. <i>Heart Rhythm</i> , 2010, 7, 699-700.	0.7	1
48	Mechanisms of Malfunction and Complications of the Subcutaneous ICD. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 297-306.	1.7	0
49	A farewell to subjectivity using multivariate analytical models to improve patient outcomes and lower costs. <i>Heart Rhythm</i> , 2015, 12, 1574-1575.	0.7	0
50	Letter by Brouwer et al Regarding Article, "Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry" <i>Circulation</i> , 2018, 138, 2970-2971.	1.6	0